World First MMJ for MCL in Autoimmune Disease Rese
Post# of 7008
(Total Views: 289)
Posted On: 03/23/2018 8:44:52 AM
World First MMJ for MCL in Autoimmune Disease Research.Feb 26, 2018 - (ABN Newswire) MCL subsidiary of QBL.
2 Days ago; QBL HALF-YEAR Report; Milestones, Finances and More !
Another dot connecting... all the parts getting togheter in success.
SUMMARY at the bottom part of the news. Important; The "BIG LETTER" part.
http://www.4-traders.com/QUEENSLAND-BAUXITE-L...-26053610/
The Board of Queensland Bauxite Limited (ASX:QBL) is pleased to announce that its subsidiary company Medical Cannabis Limited (MCL) through its wholly owned subsidiary Medical Cannabis Research Group Pty Ltd (MCRG), has signed a Research Funding Agreement with the Research & Development Foundation at the Technion Institute, Haifa, Israel. The agreement revolves around the research of Prof. David (Dedi) Meiri, from the Faculty of Biology at the Technion Institute.
Cannabis as a Potential Therapy for Multiple Sclerosis
According to the agreement MCRG will sponsor the continued Research of how the cannabis plant can be used for the treatment of Multiple Sclerosis (MS). Prof. Meiri has identified the synergistic relationship between the Cannabis plant and the human genome that will form the basis for this research.
Highlights
- Medical Cannabis Ltd (MCL) a subsidiary of Queensland Bauxite Limited (ASX:QBL), completes an arrangement to sponsor research into medical cannabis treatments for Multiple Sclerosis (MS).
- MCL through its Medical Cannabis Research Group Pty Ltd (MCRG) has signed an agreement with the Technion Research & Development Foundation for the performance of research by Prof. David (Dedi) Meiri, from the Faculty of Biology at the Technion - Israel Institute of Technology in Haifa, Israel. Prof. Meiri is Head of the Technion's Cannabis research team. According to the agreement, MCRG will sponsor research into how the cannabis plant can be used in the treatment of symptoms and halting the progression of autoimmune diseases with special emphasis on Multiple Sclerosis (MS).
(Want to read the whole piece ? Go to board for full story)
QBL have also started a interactive webpage on Facebook
Read More: https://investorshangout.com/post/view?id=496...z5A0Kvlko9
Read More: https://investorshangout.com/post/view?id=497...z5A7RmzeS0
Read More: https://investorshangout.com/post/view?id=497...z5ACr8SZnG
Read More: https://investorshangout.com/post/view?id=497...z5AOz67Y5h
Read More: https://investorshangout.com/post/view?id=497...z5ATq0fesm
Read More: https://investorshangout.com/post/view?id=497...z5AZjZnZH6
2 Days ago; QBL HALF-YEAR Report; Milestones, Finances and More !
Another dot connecting... all the parts getting togheter in success.
SUMMARY at the bottom part of the news. Important; The "BIG LETTER" part.
http://www.4-traders.com/QUEENSLAND-BAUXITE-L...-26053610/
The Board of Queensland Bauxite Limited (ASX:QBL) is pleased to announce that its subsidiary company Medical Cannabis Limited (MCL) through its wholly owned subsidiary Medical Cannabis Research Group Pty Ltd (MCRG), has signed a Research Funding Agreement with the Research & Development Foundation at the Technion Institute, Haifa, Israel. The agreement revolves around the research of Prof. David (Dedi) Meiri, from the Faculty of Biology at the Technion Institute.
Cannabis as a Potential Therapy for Multiple Sclerosis
According to the agreement MCRG will sponsor the continued Research of how the cannabis plant can be used for the treatment of Multiple Sclerosis (MS). Prof. Meiri has identified the synergistic relationship between the Cannabis plant and the human genome that will form the basis for this research.
Highlights
- Medical Cannabis Ltd (MCL) a subsidiary of Queensland Bauxite Limited (ASX:QBL), completes an arrangement to sponsor research into medical cannabis treatments for Multiple Sclerosis (MS).
- MCL through its Medical Cannabis Research Group Pty Ltd (MCRG) has signed an agreement with the Technion Research & Development Foundation for the performance of research by Prof. David (Dedi) Meiri, from the Faculty of Biology at the Technion - Israel Institute of Technology in Haifa, Israel. Prof. Meiri is Head of the Technion's Cannabis research team. According to the agreement, MCRG will sponsor research into how the cannabis plant can be used in the treatment of symptoms and halting the progression of autoimmune diseases with special emphasis on Multiple Sclerosis (MS).
(Want to read the whole piece ? Go to board for full story)
QBL have also started a interactive webpage on Facebook
Read More: https://investorshangout.com/post/view?id=496...z5A0Kvlko9
Read More: https://investorshangout.com/post/view?id=497...z5A7RmzeS0
Read More: https://investorshangout.com/post/view?id=497...z5ACr8SZnG
Read More: https://investorshangout.com/post/view?id=497...z5AOz67Y5h
Read More: https://investorshangout.com/post/view?id=497...z5ATq0fesm
Read More: https://investorshangout.com/post/view?id=497...z5AZjZnZH6
(0)
(0)
Robert
Scroll down for more posts ▼